person · Reporting owner

Ryan Jason

Disclosed activity across 5 companies

Tapewire entity: 36008
SEC CIK: 0001585017

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	See Remarks	February 10, 2020	February 12, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date February 10, 2020 · Filed February 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.28 · Expires 2030-02-09	Direct	75,000	Reported balance After 2020-02-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-10 · Grant · Acquired 75,000 · Balance 75,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-07-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-31 · Other · Disposed 6,955 · Balance 42,215 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 42,215 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-21	Direct	0	Reported balance After 2018-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-31 · Other · Disposed 1,562 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.

F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.

F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.

GeneDx Holdings Corp.

Report date June 18, 2026 · Filed June 23, 2026

Section 16 reporting ended · disclosed 2026-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	15,480	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 15,480 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Jason Ryan 2024 GRAT	103,284	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 103,284 F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant.

F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Singular Genomics Systems, Inc.

Report date February 21, 2025 · Filed February 25, 2025

Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05	Direct	Reported balance After 2025-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-02-21 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26	Direct	Reported balance After 2025-02-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25	Direct	Reported balance After 2025-02-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29	Direct	Reported balance After 2025-02-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 10, 2024

Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07	Direct	Reported balance After 2024-01-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 185,400 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07	Direct	Reported balance After 2024-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 14,650 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 3,400 · Balance 0 F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and

F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),

F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 20:31 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	3,576	$0.00	$0.00	Disclosure SEC source: 0001585017-26-000002 · form4-06232026_080617.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F3 · derivative.expiration_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 20:31 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	3,576	$0.00	$0.00	Disclosure SEC source: 0001585017-26-000002 · form4-06232026_080617.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	1,150	$129.65	$149,093.02	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 7 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.50 to $129.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	1,500	$130.01	$195,015.45	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 6 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 103,284 F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.91 to $130.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	9,890	$129.59	$1,281,689.61	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 5 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 104,784 F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.89 to $129.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	3,452	$128.04	$441,996.84	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 4 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 114,674 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.76 to $128.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	5,443	$127.44	$693,641.22	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 118,126 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.76 to $127.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	8,969	$126.15	$1,131,471.64	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 123,569 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.655 to $126.62 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
August 27, 2025 Filed Aug 28, 2025 01:01 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	8,818	$125.07	$1,102,892.83	Disclosure SEC source: 0001415889-25-023190 · form4-08282025_010846.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan 2024 GRAT Disclosed balance after: 132,538 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.50 to $125.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT. Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:48 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	12,924	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017990 · form4-06232025_090642.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:48 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GrantRestricted Stock Unit · Derivative	3,576	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017990 · form4-06232025_090642.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,576 Underlying: Class A Common Stock · 3,576 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:48 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	12,924	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017990 · form4-06232025_090642.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:08 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	Disposition to issuerStock Option (Right to Buy) · Derivative	2,466	$8.84 Strike: $11.16	$21,799.44	Disclosure SEC source: 0000950170-25-027101 · ownership.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,466 shares Expires 2034-05-29 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2 · derivative.exercise_date: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:08 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	Disposition to issuerStock Option (Right to Buy) · Derivative	2,466	$0.00 Strike: $31.80	$0.00	Disclosure SEC source: 0000950170-25-027101 · ownership.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,466 shares Expires 2033-05-25 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2 · derivative.exercise_date: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:08 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	Disposition to issuerStock Option (Right to Buy) · Derivative	1,541	$0.00 Strike: $85.80	$0.00	Disclosure SEC source: 0000950170-25-027101 · ownership.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,541 shares Expires 2032-05-26 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2 · derivative.exercise_date: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:08 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	Disposition to issuerStock Option (Right to Buy) · Derivative	1,333	$0.00 Strike: $672.90	$0.00	Disclosure SEC source: 0000950170-25-027101 · ownership.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2031-05-05 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2 · derivative.exercise_date: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Read SEC document
November 20, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	4,272	$70.50	$301,184.54	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 7 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan u/a dtd 11/25/2018 Disclosed balance after: 0 F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.22 to $70.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 20, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	1,857	$69.84	$129,688.98	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 6 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 4,272 F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.22 to $70.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 20, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	9,361	$68.36	$639,875.84	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 5 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 6,129 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.01 to $68.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 19, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	774	$72.26	$55,926.53	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 4 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 15,490 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.12 to $72.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 19, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	24,784	$71.35	$1,768,420.19	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 16,264 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.04 to $72.0302 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 19, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	5,952	$70.86	$421,783.72	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 41,048 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.026 to $71.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 19, 2024 Filed Nov 22, 2024 01:21 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GiftClass A Common Stock	141,356	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027473 · form4-11222024_011124.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 47,000 F1 · ownership.direct: On November 19, 2024, the reporting person transferred 141,356 shares of GeneDx Holdings Corp. Class A common stock from the reporting person's indirect holdings to the Jason Ryan 2024 GRAT (the "GRAT") for no consideration. The reporting person is the trustee of the GRAT, and the reporting person is the sole annuitant of the grantor retained annuity trust. The reporting person remains the beneficial owner of the securities held by the grantor retained annuity trust. Read SEC document
October 15, 2024 Filed Oct 17, 2024 21:47 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	130	$0.00	$0.00	Disclosure SEC source: 0001415889-24-025386 · form4-10172024_091007.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
October 15, 2024 Filed Oct 17, 2024 21:47 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	130	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-025386 · form4-10172024_091007.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
June 26, 2024 Filed Jun 27, 2024 20:15 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GrantRestricted Stock Unit · Derivative	12,924	$0.00	$0.00	Disclosure SEC source: 0001415889-24-018329 · form4-06272024_080631.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,924 Underlying: Class A Common Stock · 12,924 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
May 29, 2024 Filed May 31, 2024 18:30 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	GrantStock Option (Right to Buy) · Derivative	74,000	$0.00 Strike: $0.37	$0.00	Disclosure SEC source: 0000950170-24-067530 · ownership.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025. Read SEC document
January 11, 2024 Filed Jan 12, 2024 21:31 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GiftClass A Common Stock	73,614	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001523 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · balance_after: On January 11, 2024, the reporting person transferred 73,614 shares of GeneDx Holdings Corp. Class A common stock to the Jason Ryan Trust u/a dtd 11/25/2018 for no consideration. The reporting person is the trustee of the trust, and the reporting person and his spouse are the sole beneficiaries of the trust. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:53 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	3,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001332 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,400 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F8 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F7 · derivative.exercise_date: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. F7 · derivative.expiration_date: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:53 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (right to buy) · Derivative	14,650	Not disclosed Strike: $2.74	Not disclosed	Disclosure SEC source: 0001209191-24-001332 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,650 shares Expires 2033-06-07 F2 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3 · price: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4 · price: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5 · derivative.exercise_date: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:53 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (right to buy) · Derivative	185,400	Not disclosed Strike: $2.74	Not disclosed	Disclosure SEC source: 0001209191-24-001332 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F2 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3 · price: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4 · price: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1 · derivative.exercise_date: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
December 31, 2023 Filed Jan 3, 2024 21:23 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	46,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000371 · doc4.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 46,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. F2 · derivative.expiration_date: 100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
December 31, 2023 Filed Jan 3, 2024 21:23 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	21,780	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000371 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 21,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. F2 · derivative.expiration_date: 100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
December 31, 2023 Filed Jan 3, 2024 21:23 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	67,780	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000371 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
November 17, 2023 Filed Nov 20, 2023 21:32 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	58,000	$1.54	$89,180.80	Disclosure SEC source: 0001209191-23-056073 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 114,742 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
November 16, 2023 Filed Nov 20, 2023 21:32 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	56,742	$1.27	$72,187.17	Disclosure SEC source: 0001209191-23-056073 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Jason Ryan Trust u/a dtd 11/25/2018 Disclosed balance after: 56,742 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.175 to $1.395, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
October 17, 2023 Filed Oct 18, 2023 20:59 UTC	GeneDx Holdings Corp. WGS · Entity 1634	SaleClass A Common Stock	42	$3.19	$133.98	Disclosure SEC source: 0001209191-23-053094 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,834 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document
October 15, 2023 Filed Oct 17, 2023 22:50 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	129	$0.00	$0.00	Disclosure SEC source: 0001209191-23-053013 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130 Underlying: Class A Common Stock · 129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
October 15, 2023 Filed Oct 17, 2023 22:50 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	129	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-053013 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:25 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantRestricted Stock Unit (RSU) · Derivative	3,400	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036547 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 3,400 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. F4 · derivative.expiration_date: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:25 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (Right to Buy) · Derivative	14,650	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-23-036547 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,650 Underlying: Common Stock · 14,650 shares Expires 2033-06-07 F2 · derivative.exercise_date: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:25 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (Right to Buy) · Derivative	185,400	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-23-036547 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,400 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/4 of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vest monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
May 25, 2023 Filed May 26, 2023 17:03 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	GrantStock Option (Right to Buy) · Derivative	74,000	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001209191-23-032600 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2024 Stockholder Annual Meeting or May 25, 2024. Read SEC document
April 26, 2023 Filed Apr 27, 2023 23:39 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GrantRestricted Stock Unit · Derivative	1,518,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-025918 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,518,000 Underlying: Class A Common Stock · 1,518,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the underlying awards shall become vested and exercisable on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. F2 · derivative.expiration_date: 100% of the underlying awards shall become vested and exercisable on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
December 31, 2022 Filed Jan 5, 2023 00:46 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	247,525	$0.00	$0.00	Disclosure SEC source: 0001209191-23-001437 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 247,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the RSUs vested as of December 31, 2022, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. F3 · derivative.expiration_date: 100% of the RSUs vested as of December 31, 2022, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
December 31, 2022 Filed Jan 5, 2023 00:46 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	SaleClass A Common Stock	73,732	$0.26	$19,310.41	Disclosure SEC source: 0001209191-23-001437 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,626 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document
December 31, 2022 Filed Jan 5, 2023 00:46 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionClass A Common Stock	247,525	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-001437 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
December 09, 2022 Filed Dec 14, 2022 21:11 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantRestricted Stock Unit · Derivative	718,753	$0.00	$0.00	Disclosure SEC source: 0001209191-22-061182 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,753 Underlying: Class A Common Stock · 718,753 shares Expires 2026-12-09 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 9, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
October 17, 2022 Filed Oct 18, 2022 22:36 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	SaleClass A Common Stock	1,281	$0.86	$1,101.40	Disclosure SEC source: 0001209191-22-054000 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document
October 15, 2022 Filed Oct 18, 2022 22:36 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	4,278	$0.00	$0.00	Disclosure SEC source: 0001209191-22-054000 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,558 Underlying: Class A Common Stock · 4,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.